MERZ-AESTHETICS
Merz Aesthetics, the world’s largest dedicated medical aesthetics business, is presenting new data for its product portfolio in addition to perspectives on medical aesthetics trends at the 2024 Aesthetic and Anti-Aging Medicine World Congress. AMWC is a leading global scientific conference specializing in aesthetic and anti-aging medicine. Participants can attend live in Monaco or tune in virtually beginning March 27 through March 29, 2024.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240321775430/en/
Merz Aesthetics’ programming includes a sponsored symposium on March 28 from 14:00 - 16:00 CET, Beauty Without Borders: Aesthetics Across Continents, moderated by Dr. Sabrina Fabi, featuring commentary from Dr. Kate Goldie, Dr. Siew Tuck Wah, Dr. Rolf Bartsch and Dr. Rossana Vasconcelos. During the session, the group will discuss the multifaceted landscape of beauty and aging around the world, the nuances and variances of aging concerns among different patient populations and the recommended techniques and products.
“Each year, AMWC allows us the opportunity to connect and collaborate with peers from around the world and provides a forum to showcase our research and advancements in medical aesthetics,” said Terri Phillips, MD, Chief Medical Affairs Officer, Merz Aesthetics. “We’re excited to engage in scientific exchange, foster new connections and discuss innovations within our portfolio, in addition to sharing insights from the evolving field of regenerative aesthetics.”
“At Merz Aesthetics, we aim to provide the best experience possible for our health care professionals and their patients,” said Gonzalo Mibelli, President, EMEA, Merz Aesthetics. “I’m looking forward to presenting our latest data and honoring the commitment we’ve made to our customers to meet their evolving needs.”
In addition to the symposium, Merz Aesthetics is presenting five e-posters for the first time. The abstracts will be available for viewing on-site throughout the congress and displayed on the virtual e-poster platform with detailed abstracts. Following are the highlighted e-posters:
- Long-term Duration and Safety of CaHA(+)-CMC for the Treatment of Jawline – Jeremy B. Green, MD, Roberta Del Campo, MD, Alan J. Durkin, MD, David K. Funt, MD, Nicole Nasrallah, MS, Keith Martinez, PhD, Amir Moradi, MD
- Tissue Integration of Hyaluronic Acid-Containing Dermal Fillers: Automated Approach Using a Human Skin Model Under Optimal Tension – Kay Marquardt, PhD, Christian Hartmann, PhD, Michael Conneely, PhD, Robyn Hickerson, PhD, Kristina Riegel, PhD, Thomas Hengl, PhD
- Stimulation of Elastin Neogenesis by Micro-Focused Ultrasound (MFU-V) – Kay Marquardt, PhD, Christian Hartmann, PhD, Flora Wegener, PhD, Nils Warfving, PhD, Kristina Riegel, PhD, Thomas Hengl, PhD
- Consensus Agreements on Regenerative Aesthetics: Terminology, Goals, and Strategies – Dr. Kate Goldie, Dr. Greg Chernoff, Dr. Niamh Corduff, Dr. Owen Davies, Dr. Jani van Loghem, Dr. Bianca Viscomi
- Micro-focused Ultrasound with Visualization and Aesthetic Outcomes: A Systematic Review and Meta-analysis of Clinical Studies – Dr. Sabrina Guillen Fabi, Dr. Gabriela Casabona, Dr. Tatjana Pavicic, Dr. Julia Sevi, Dr. Julieta Spada, Dr. Vasanop Vachiramon, Dr. Rossana Vasconcelos, Dr. Siew Tuck Wah
Merz Aesthetics will be located at Booth J1 on Level 1.
About Merz Aesthetics
Merz Aesthetics is a medical aesthetics business with a long history of empowering health care professionals, patients and employees to live every day with confidence. We aim to help people around the world look, feel and live like the best versions of themselves — however they define it. Clinically proven, its product portfolio includes injectables, devices and skin care treatments designed to meet each patient’s needs with high standards of safety and efficacy. Being family owned for more than 115 years, Merz Aesthetics is known for building unique connections with customers who feel like family. Merz Aesthetics’ global headquarters is in Raleigh, N.C., USA, with a commercial presence in 90 countries worldwide. It is also a part of Merz Group, which was founded in 1908 and is based in Frankfurt, Germany. Learn more at merzaesthetics.com.
Copyright © 2024 Merz Aesthetics GmbH. All rights reserved. MERZ, MERZ AESTHETICS and the MERZ logo are registered trademarks of Merz Pharma GmbH & Co. KGaA.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240321775430/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yokogawa Collaborates with Shell on Robotics and AI Technology for Plant Maintenance18.6.2025 08:00:00 CEST | Press release
- Streamlining operations and reducing risk in asset integrity management – Yokogawa Electric Corporation (TOKYO: 6841) announces that it has formalized a long-term agreement with Shell Global Solutions International B.V. (“Shell”) to integrate and further develop technologies for utilizing robots and drones in plant monitoring and maintenance. Under the agreement, Yokogawa will add an advanced machine vision tool called Operator Round by Exception (ORE), developed by Shell, into its own OpreX™ Robot Management Core. The enhanced software service will be made available by Yokogawa to customers in the energy, chemicals, and other industries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250617976629/en/ OpreX Robot Management Core ORE is a digital solution that uses machine vision and AI analytics to enable robots to autonomously perform a number of tasks in the operator round process, such as reading gauges and checking for
Ververica Announces Partnership with Aiven - Empowering Leading Enterprises to Create Value from their Data in Real-Time18.6.2025 08:00:00 CEST | Press release
Ververica, the original creators of Apache Flink® and a leader in stream processing technology, today announced a new partnership with Aiven, the AI-ready open source cloud data platform. This partnership enables Aiven to provide Ververica’s Unified Streaming Data Platform to their customers, expanding access to enterprise-grade streaming data capabilities for data-driven businesses around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250617806011/en/ Ververica Announces Partnership with Aiven - Empowering Leading Enterprises to Create Value from their Data in Real-Time Under the partnership, Aiven customers can now unlock enterprise-grade stream processing with Ververica’s powerful platform — allowing them to make decisions and take actions at speed with data from any source — plus expert support from the original creators of Apache Flink. “This partnership is about removing friction and delivering real business
ICD 2025: New data demonstrate Nemluvio®’s (nemolizumab) favorable safety profile and sustained and clinically meaningful improvements in symptoms of prurigo nodularis up to two years18.6.2025 07:00:00 CEST | Press release
An interim analysis of the OLYMPIA long-term extension study to be presented as a late-breaking abstract at the XIV International Congress of Dermatology (ICD) found that Nemluvio was well tolerated and associated with sustained and clinically meaningful improvements in the key signs and symptoms of prurigo nodularis, including both skin lesions and itch, up to two years1 Results build on data from OLYMPIA – the largest completed pivotal clinical program in prurigo nodularis and the only one assessing long-term safety and efficacy in prurigo nodularis1-3 This follows the presentation of data from the ARCADIA long-term extension study at the Revolutionizing Atopic Dermatitis (RAD) Conference earlier this month, which showed Nemluvio is well tolerated with sustained and increased improvements in efficacy outcomes in atopic dermatitis patients up to two years4 Galderma (SIX: GALD) today announced data from a new interim analysis of a study investigating the long-term safety and efficacy o
LabPMM® Receives New York State Approval for the NPM1 MRD Assay - Informing Therapy and Accelerating Targeted Trials18.6.2025 06:30:00 CEST | Press release
Invivoscribe is happy to announce that its wholly owned subsidiary, the Laboratory for Personalized Molecular Medicine® (LabPMM) has received approval from New York State (NYS) for the NPM1 MRD Assay. This approval comes just two months after gaining NYS approval for our FLT3 ITD MRD Assay. Together these tests represent a critical tool for patients with acute myeloid leukemia (AML), clinicians and pharmaceutical companies. This new approval underscores Invivoscribe’s ongoing commitment to providing the most accurate, standardized measurable residual disease (MRD) testing solutions worldwide. The NPM1 MRD Assay is a pivotal development in the fight against AML, offering an ultra-sensitive DNA sequencing method to accurately measure trace levels of residual leukemia cells in patients with the NPM1 mutation variants. NPM1 mutations are considered an ideal target for MRD assessment because they are present in ~30% of adult AML cases,1 stable over time,2 and, if present in blood at allele
DNP to Take Controlling-Stake in Laxton18.6.2025 03:30:00 CEST | Press release
Maximizing synergies to accelerate the global expansion of biometric info-driven government authentication and security business Dai Nippon Printing Co., Ltd. (DNP, TOKYO: 7912) entered into a share transfer agreement on June 17, 2025 to acquire Cayman Islands-headquartered Rubicon SEZC. Rubicon (a holding company of “Laxton” group) is a global Identity Systems Integrator that provides ID solutions for governments, primarily in developing nations, to register and authenticate personal information. DNP plans to acquire 75% of Rubicon's shares in July and complete the procedures to make the company a Group company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250613922077/en/ Products of Laxton DNP will maximize synergies with Laxton in ID cards and card printers. By expanding to government-related business in Africa, Asia, South America, and other regions, we will further grow our authentication and security business, contr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom